Prosecution Insights
Last updated: August 16, 2026
Application No. 18/305,609

ORGANIC COMPOUND, LIGHT-EMITTING DEVICE, AND LIGHT-EMITTING APPARATUS

Non-Final OA §112
Filed
Apr 24, 2023
Priority
Apr 29, 2022 — JP 2022-075573 +3 more
Examiner
KENYON, JOHN S
Art Unit
1625
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Semiconductor Energy Laboratory Co., Ltd.
OA Round
1 (Non-Final)
80%
Grant Probability
Favorable
1-2
OA Rounds
0m
Est. Remaining
98%
With Interview

Examiner Intelligence

Grants 80% — above average
80%
Career Allowance Rate
758 granted / 945 resolved
+20.2% vs TC avg
Strong +18% interview lift
Without
With
+17.5%
Interview Lift
resolved cases with interview
Typical timeline
2y 4m
Avg Prosecution
56 currently pending
Career history
991
Total Applications
across all art units

Statute-Specific Performance

§101
4.1%
-35.9% vs TC avg
§103
16.3%
-23.7% vs TC avg
§102
22.0%
-18.0% vs TC avg
§112
42.0%
+2.0% vs TC avg
Black line = Tech Center average estimate • Based on career data from 945 resolved cases

Office Action

§112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. Election/Restrictions Applicant’s election in the reply filed on 20 January 2026, is acknowledged. Because applicant did not distinctly and specifically point out the supposed errors in the restriction requirement, the election has been treated as an election without traverse (MPEP § 818.01(a)). Applicants provided a compliant species election of compound 101: PNG media_image1.png 152 206 media_image1.png Greyscale , as a species of genus formula G1 of instant claim 1, wherein R2 and R7 are each a t-butyl (branched C4alkyl); R1, R3, R4, R5, R6, R8, R9, R10, R11, R12, R13, R14, and R16 are each hydrogen (H); and R15 represents PNG media_image2.png 106 324 media_image2.png Greyscale . This elected species is free of the prior art. The Examiner extended the Markush search to the full scope of genus formula G1 of instant claims 1 and 18 but did not find any prior art. Applicants provided a compliant species election of compound 100: PNG media_image3.png 142 220 media_image3.png Greyscale , as a species of genus formula G3 of instant claim 9, wherein: R2 and R7 are each a t-butyl (branched C4alkyl); R1, R3, R4, R5, R6, and R8 are H. This elected species is free of the prior art. The Examiner extended the Markush search to the full scope of genus formula G2 and G3 of instant claim 9 but did not find any prior art. Therefore, the Election of Species Requirement of 19 November 2025, is withdrawn, as all claims are free of the prior art. All claims have been examined on the merits. Current Status of 18/305,609 This Office Action is responsive to the amended claims of 20 January 2026. Claims 1-20 have been examined on the merits. Claims 1-3 and 18-19 are currently amended. Claims 4-17 and 20 are original. Priority The effective filing date is 24 April 2023. Receipt is acknowledged of certified copies of papers required by 37 CFR 1.55. Information Disclosure Statement The information disclosure statement (IDS) submitted on 11 August 2023, is in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement is being considered by the examiner. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 4, 13, and 19 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 4 recites the limitation "at least one deuterium is included". There is insufficient antecedent basis for this limitation in the claim. As drafted, the limitation "at least one deuterium is included" renders the metes and bounds of claim 4 undefined (hence rendering claim 4 indefinite under 35 USC 112(b)). The artisan does not know where antecedent basis for “deuterium” is found within parent claim 1. In fact, claim 1 is silent as to “deuterium”. Similarly, claim 13 is also rejected under 35 USC 112(b) indefiniteness since “deuterium” does not have antecedent basis within parent claim 9. The term “substantially” in claim 19 is a relative term which renders the claim indefinite. The term “substantially” is not defined by the claim, the specification does not provide a standard for ascertaining the requisite degree, and one of ordinary skill in the art would not be reasonably apprised of the scope of the invention. As drafted, “substantially aligned” within claim 19 renders the metes and bounds of claim 19 undefined (hence rendering claim 19 indefinite under 35 USC 112(b)). Neither the Specification nor the claims define the standard to ascertain by what requisite degree one of ordinary skill is to measure “substantially aligned”. Applicants can strike “substantially aligned” to render moot this rejection. The following is a quotation of 35 U.S.C. 112(d): (d) REFERENCE IN DEPENDENT FORMS.—Subject to subsection (e), a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. The following is a quotation of pre-AIA 35 U.S.C. 112, fourth paragraph: Subject to the following paragraph [i.e., the fifth paragraph of pre-AIA 35 U.S.C. 112], a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. Claims 4 and 13 are rejected under 35 U.S.C. 112(d) or pre-AIA 35 U.S.C. 112, 4th paragraph, as being of improper dependent form for failing to further limit the subject matter of the claim upon which it depends, or for failing to include all the limitations of the claim upon which it depends. Dependent claim 4, drawn to the limitation "at least one deuterium is included”, does not properly further limit parent claim 1, which is silent as to “deuterium”. Therefore, claim 4 is rejected under 35 USC 112(d). Similarly, claim 13 is also rejected under 35 USC 112(d) since “deuterium” is not found within parent claim 9. Applicant may cancel the claim(s), amend the claim(s) to place the claim(s) in proper dependent form, rewrite the claim(s) in independent form, or present a sufficient showing that the dependent claim(s) complies with the statutory requirements. Conclusion Claims 4, 13, and 19 are not presently allowable as written. Claims 1-3, 5-12, 14-18, and 20 are presently allowable as written. There is no known prior art reference that either teaches or anticipates a compound of genus formula G1 from instant claims 1 and/or 18. The reference NIPPON (U.S. 2022/0310937 A1, referenced in IDS of 11 August 2023), discloses the compound: PNG media_image4.png 164 334 media_image4.png Greyscale (page 24), wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R11, R12, R13, R14, and R16 are each hydrogen (H); and R10 and R15 represents PNG media_image2.png 106 324 media_image2.png Greyscale . However, NIPPON is a close art but not a prior art reference because (1) the compound also contains a heterocycle PNG media_image2.png 106 324 media_image2.png Greyscale at R10 which is not permitted by instant claims 1 and 16. While claims 1 and 16 permit a cycloalkyl and a heteroaryl (closest rings to g1-1, above), the extra g1-1 is neither a cycloalkyl nor a heteroaryl. Also, (2) the compound, above, is really the only compound one could immediately envisage from NIPPON. This exemplary compound is also disclaimed by instant claim 9 as it only contains hydrogen atoms at R1, R2, R3, R4, R5, R6, R7, R8. Any inquiry concerning this communication or earlier communications from the examiner should be directed to JOHN S KENYON whose telephone number is (571)270-1567. The examiner can normally be reached Monday-Friday 10a-6p. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Andrew D Kosar can be reached at (571) 272-0913. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /JOHN S KENYON/Primary Patent Examiner, Art Unit 1625
Read full office action

Prosecution Timeline

Apr 24, 2023
Application Filed
May 12, 2026
Non-Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12702657
Treatment and Prevention of Dengue Disease
4y 3m to grant Granted Aug 11, 2026
Patent 12702676
Methods of Identifying Novel Dosing Regimens
3y 7m to grant Granted Aug 11, 2026
Patent 12698262
Potassium salt of 2-[(4S)-8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-4H-quinazolin-4-yl]acetic acid
3y 11m to grant Granted Aug 04, 2026
Patent 12690590
PHENYL COMPOUND AND PLANT DISEASE CONTROL METHOD
3y 9m to grant Granted Jul 28, 2026
Patent 12686678
CRYSTAL FORM OF LANIFIBRANOR, PREPARATION METHOD THEREFOR, AND USE THEREOF
2y 8m to grant Granted Jul 21, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
80%
Grant Probability
98%
With Interview (+17.5%)
2y 4m (~0m remaining)
Median Time to Grant
Low
PTA Risk
Based on 945 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month